

member hospitals to preferred medical suppliers on the GPO contracts. The higher the expenditures, the higher the GPO compensation.

The obvious problem with this arrangement is that it reduces incentives for GPOs to bargain for the lowest prices. The less their hospital members pay, the less GPOs receive in administrative fees. In a 2006 report, one of us estimated that if this GPO safe-harbor provision were removed, GPO-member hospitals would keep an additional 21 to 32 percent of the administrative fees (net of operating expenses) currently paid to GPOs but not passed through to member hospitals. This saving would have been substantial – roughly half a billion dollars per year. The report also estimated the overcharges to the federal government relating to Medicare reporting problems; relative to direct payment of rebates by manufacturers, hospitals tend not to credit indirect, lump-sum payments of rebates from GPOs to individual medical device purchases on their cost reports, leading to cost overruns.

In a new study on GPOs, we estimated the anticompetitive impact on medical supply prices attributable to the GPO safe harbor. To assess whether GPOs are in fact securing the lowest possible prices for hospitals, we analyzed “aftermarket” transactions for medical supplies – that is, we examine the prices of medical supplies that are rebid by hospitals after the GPOs have supposedly secured the “best” price. If the original GPO auctions are designed efficiently, then there should not be significant room for price improvement in the aftermarket.

Our findings clearly are inconsistent with the notion that GPOs are securing competitive prices for their member hospitals. When exposed to competition in the aftermarket, hospitals enjoy an average price reduction of 10 percent from 2001 through 2010, and an average price reduction of 15 percent in 2010. When incumbent device makers are induced to bid against their GPO bid (which occurs in roughly 52 percent of the auctions), they reduce their prices by seven percent on average; in 10 percent of these occasions, the incumbent dropped its own price by 15 percent or more. These systematic and significant savings would not be possible if GPOs secured competitive prices for their member hospitals.

One clear policy implication of these findings is to modify the incentives that limit the intended pro-competitive objectives of GPOs – namely, by changing the method of compensation of GPOs to reduce conflicts of interest. **This could be achieved by reinstating the application of the existing anti-kickback statute of the 1986 Social Security Act, thereby prohibiting vendors from paying GPOs.** This exemption has allowed GPOs to retain an equity interest (or its functional equivalent) in their contracts with those with whom they are to negotiate for lower prices.

So long as GPOs are compensated this way, they have an inherent conflict that limits their ability to negotiate the best prices for their member hospitals and those hospitals (and their payors, including the federal government) will likely continue to overpay for medical devices. Changing the incentive structure by reapplying the anti-kickback statutes would reduce private U.S. health care expenditures by up to \$37.5 billion annually, and would reduce federal health care spending by up to \$17.25 billion annually.

Repealing the safe harbor would not threaten the existence of GPOs; they would have to secure funding from their principals, as they should. But this reform would help “bend the cost curve” in a dramatic way for U.S. health care consumers. And it would unleash a new wave of innovation in medical technology, as entrants would be encouraged to take new risks knowing that their products would be judged on the merits of their designs, and not on side payments to GPOs.

Robert E. Litan is Vice President for Research and Policy at the Kauffman Foundation in Kansas City and a Senior Fellow in Economic Studies at the Brookings Institute. He has served in a number of federal government positions, including Associate Director of the Office of Management and Budget (1995-96) and Deputy Assistant Attorney General in the Justice Department’s Antitrust Division (1993-95). Hal J. Singer is a Managing Director at Navigant Economics and has served as adjunct professor at the McDonough School of Business at Georgetown University. The views expressed here are those of the authors and should not be attributed to their employers.

Robert E. Litan is Vice President for Research and Policy at the Kauffman Foundation in Kansas City and a Senior Fellow in Economic Studies at the Brookings Institute. Hal J. Singer is a Managing Director at Navigant Economics and has served as adjunct professor at the McDonough School of Business at Georgetown University.

This article is about GOVERNMENT

 FOLLOW THIS TOPIC

Related Topics: COSTS | HEALTHCARE

Comments

Leave a Comment

POST

0 COMMENTS

 JOIN THE CONVERSATION

POSTING GUIDELINES

We hope the conversations that take place on HBR.org will be energetic, constructive, and thought-provoking. To comment, readers must sign in or register. And to ensure the quality of the discussion, our moderating team will review all comments and may edit them for clarity, length, and relevance. Comments that are overly promotional, mean-spirited, or off-topic may be deleted per the moderators' judgment. All postings become the property of Harvard Business Publishing.